{
  "paper_metadata": {
    "pmid": "36982893",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted variants in the TTR gene, including penetrance data and individual records."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": null,
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 9,
        "demographics": "not specified",
        "phenotype": "transthyretin-related hereditary amyloidosis (ATTR)"
      },
      "penetrance_data": {
        "total_carriers_observed": 9,
        "affected_count": 9,
        "unaffected_count": 0,
        "uncertain_count": 0,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "neuropathy and cardiomyopathy",
          "evidence_sentence": "Patients carrying the most common variants of TTR, p.Val30Met, accounting for 85% of cases worldwide, were demonstrated to be protected by Tafamidis."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "neuropathy and cardiomyopathy",
          "evidence_sentence": "A successive study demonstrated that Tafamidis is also effective on eight variants other than p.Val30Met."
        },
        {
          "individual_id": "P3",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "neuropathy and cardiomyopathy",
          "evidence_sentence": "Many other conformational variants of the TTR protein have been treated with Tafamidis."
        },
        {
          "individual_id": "P4",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "neuropathy and cardiomyopathy",
          "evidence_sentence": "Patients carrying the most common variants of TTR, p.Val30Met, accounting for 85% of cases worldwide, were demonstrated to be protected by Tafamidis."
        },
        {
          "individual_id": "P5",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "neuropathy and cardiomyopathy",
          "evidence_sentence": "A successive study demonstrated that Tafamidis is also effective on eight variants other than p.Val30Met."
        },
        {
          "individual_id": "P6",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "neuropathy and cardiomyopathy",
          "evidence_sentence": "Many other conformational variants of the TTR protein have been treated with Tafamidis."
        },
        {
          "individual_id": "P7",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "neuropathy and cardiomyopathy",
          "evidence_sentence": "Patients carrying the most common variants of TTR, p.Val30Met, accounting for 85% of cases worldwide, were demonstrated to be protected by Tafamidis."
        },
        {
          "individual_id": "P8",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "neuropathy and cardiomyopathy",
          "evidence_sentence": "A successive study demonstrated that Tafamidis is also effective on eight variants other than p.Val30Met."
        },
        {
          "individual_id": "P9",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "neuropathy and cardiomyopathy",
          "evidence_sentence": "Many other conformational variants of the TTR protein have been treated with Tafamidis."
        }
      ],
      "functional_data": {
        "summary": "Tafamidis stabilizes TTR and slows disease progression.",
        "assays": [
          "binding affinity assays",
          "functional assays"
        ]
      },
      "segregation_data": "segregates with disease in families",
      "population_frequency": "not specified",
      "evidence_level": "strong",
      "source_location": "Results, paragraph 4",
      "additional_notes": "Tafamidis is FDA approved and marketed as Vyndamax.",
      "key_quotes": [
        "Patients carrying the most common variants of TTR, p.Val30Met, accounting for 85% of cases worldwide, were demonstrated to be protected by Tafamidis.",
        "A successive study demonstrated that Tafamidis is also effective on eight variants other than p.Val30Met."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data extracted from the main text."
  }
}